Can urine lamivudine be used to monitor antiretroviral treatment adherence?
Patient adherence to treatment is an important factor in the effectiveness of antiretroviral regimens. Adherence to treatment could be monitored by estimation of antiretroviral drugs in biological fluids. We aimed to obtain information on the quantity and duration of excretion of lamivudine in urine following oral administration of a single dose of 300 mg and to assess its suitability for adherence monitoring purposes. Spot urine samples were collected before dosing and at 4, 8, 12, 24, 28, 32, 48, 72, and 96 hours post dosing from 10 healthy subjects, and lamivudine was estimated by high-pressure liquid chromatography (HPLC). Lamivudine values were expressed as a ratio of urine creatinine. About 91% of the ingested drug was excreted by 24 hours, and the concentration thereafter in urine was very negligible. A lamivudine value of 0.035 mg/mg creatinine or less at 48 hours is suggestive of a missed dose in the last 24 hours. The study findings showed that estimation of urine lamivudine in spot specimens could be useful in monitoring patient adherence to antiretroviral treatment. However, this needs to be confirmed on a larger sample size and among patients on once-daily and twice-daily treatment regimens.
Kumar
Agibothu K Hemanth
AK
Tuberculosis Research Centre (ICMR) Chetput, Chennai, India.
Ramachandran
Geetha
G
Kumar
Periyaiyah
P
Kumaraswami
Vasanthapuram
V
Swaminathan
Soumya
S
D000293:Adolescent; D000328:Adult; D019380:Anti-HIV Agents / Q000627:therapeutic use / Q000652:urine*; D005260:Female; D015658:HIV Infections / Q000188:drug therapy / Q000652:urine; D006801:Humans; D019259:Lamivudine / Q000627:therapeutic use / Q000652:urine*; D008297:Male; D008991:Monitoring, Physiologic / Q000379:methods; D010349:Patient Compliance
D019380:Anti-HIV Agents; D019259:Lamivudine